AnaptysBio (ANAB) Expected to Announce Quarterly Earnings on Thursday

AnaptysBio (NASDAQ:ANAB - Get Free Report) is anticipated to post its Q1 2025 quarterly earnings results before the market opens on Thursday, May 8th. Analysts expect AnaptysBio to post earnings of ($1.30) per share and revenue of $15.27 million for the quarter.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The biotechnology company reported ($1.28) EPS for the quarter, beating the consensus estimate of ($1.30) by $0.02. The firm had revenue of $27.77 million during the quarter, compared to the consensus estimate of $15.27 million. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. On average, analysts expect AnaptysBio to post $-6 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

AnaptysBio Trading Up 2.6 %

Shares of AnaptysBio stock traded up $0.54 during trading on Tuesday, hitting $21.27. The stock had a trading volume of 40,449 shares, compared to its average volume of 589,068. The firm has a market cap of $628.89 million, a price-to-earnings ratio of -3.48 and a beta of -0.20. AnaptysBio has a 12 month low of $12.21 and a 12 month high of $41.31. The business's 50-day moving average is $18.32 and its 200 day moving average is $18.91.

AnaptysBio declared that its Board of Directors has authorized a share repurchase program on Monday, March 24th that allows the company to repurchase $75.00 million in outstanding shares. This repurchase authorization allows the biotechnology company to purchase up to 13.1% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company's leadership believes its shares are undervalued.

Wall Street Analyst Weigh In

Several research analysts have recently commented on ANAB shares. HC Wainwright reissued a "neutral" rating and set a $22.00 price objective on shares of AnaptysBio in a report on Tuesday, March 4th. JPMorgan Chase & Co. boosted their price target on shares of AnaptysBio from $36.00 to $42.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 5th. Wedbush reaffirmed an "outperform" rating and set a $40.00 price objective on shares of AnaptysBio in a report on Thursday, May 1st. Guggenheim upped their target price on shares of AnaptysBio from $52.00 to $54.00 and gave the stock a "buy" rating in a research report on Tuesday. Finally, Wolfe Research assumed coverage on AnaptysBio in a research note on Tuesday, February 4th. They set an "outperform" rating and a $25.00 price target for the company. Four investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, AnaptysBio currently has a consensus rating of "Moderate Buy" and a consensus target price of $35.88.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.